BridgeBio Pharma BBIO Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLinesOfCredit.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's debt repayments?
- BridgeBio Pharma (BBIO) reported debt repayments of $0 in Q1 2026.
- How has BridgeBio Pharma's debt repayments changed year-over-year?
- BridgeBio Pharma's debt repayments decreased by 100.0% year-over-year, from $459M to $0.
- What does debt repayments mean?
- Cash used to pay down the principal amount of borrowed debt.
- How do you interpret debt repayments?
- Higher repayments indicate active debt reduction and improved solvency, while lower repayments may suggest reliance on debt financing or liquidity constraints.
- How does debt repayments compare across companies?
- Varies significantly based on the company's capital structure and debt maturity schedule.